Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyAntitumor activity of lurbinectedin in relapsed ES

Overview of attention for article published in Clinical Cancer Research, April 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 332 X posts from 141 X users, with an upper bound of 672,727 followers.

RT @VivekSubbiah: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sar…

RT @VivekSubbiah: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sar…

RT @VivekSubbiah: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sar…

RT @VivekSubbiah: Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sar…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 328 additional X posts.